A Phase 3 interventional study of Amlenetug and Placebo in Multiple System Atrophy, sponsored by H. Lundbeck A/S. Active, not recruiting at 74 sites in 10 countries. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-10-14.
Sponsored by H. Lundbeck A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 90 studies in Multiple System Atrophy with a site in United States — 21 open to participants now, 32 under way, 1 of them phase 3. Multiple System Atrophy · United States.
Among the 90 studies in Multiple System Atrophy with a site in United States, this one is the 6th largest by enrollment of the 57 interventional ones that give a count, is one of 4 that started in 2024, is one of 7 in phase 3, reaches primary completion later than 24 of the 31 other live ones, and was the 82nd registered.
207 studies on the registry are indexed under Multiple System Atrophy; 73 are open to participants now.
Browse Multiple System Atrophy studies →21 of the 90 studies in Multiple System Atrophy with a site in United States are open now. Recruiting first, the newest first:
Prabesh Kanel · Sites in United States
Ages 45+
MODAG GmbH · Sites in United States
Ages 18–60 · Healthy volunteers
MODAG GmbH · Sites in United States
Ages 50–80 · Healthy volunteers
Teva Branded Pharmaceutical Products R&D LLC · Sites in United States, France, Germany and 4 more countries
Ages 30+
Tiziana Life Sciences LTD · Sites in United States
Ages 30–85
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 57 Multiple System Atrophy studies recruiting now, 24 (42%) set no upper age limit and 11 (19%) stop at 75 or younger; 7 take children under 18; 18 take healthy volunteers.
This study: 40 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
90 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 20 · Phase 3 7 · Phase 4 2
First in 1995; this study’s year is marked. 4 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 401 is above the median of 41 across 134 interventional studies indexed under Multiple System Atrophy.
Median enrollment 35 across the 57 interventional studies, 184 across the 31 observational. Of the 53 that completed or were terminated, 19 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 90 have an industry lead sponsor. The 10 most frequent:
H. Lundbeck A/S is the lead sponsor of 224 studies on the registry; 9 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 10 (30%) have results posted.
H. Lundbeck A/S has 7 studies filed under Multiple System Atrophy — fewer than ten, so there is no comparison to draw.
19 of the studies in Multiple System Atrophy with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06098612Massachusetts General HospitalPET Imaging Evaluation of [11C]SY08 | 2026-11 |
| NCT03042988Vanderbilt University Medical CenterOvernight Trials With Heat Stress in Autonomic Failure Patients With Supine Hypertension | 2026-11-30 |
| NCT05167721Mayo ClinicRandomized Double-Blind Placebo-Controlled Adaptive Design Trial Of Intrathecally Administered Autologous Mesenchymal Stem Cells In Multiple System Atrophy | 2026-12 |
| NCT02726711Vanderbilt UniversityReduction in Splanchnic Capacitance Contributes to Sympathetically Dependent Hypertension in Autonomic | 2026-12 |
| NCT03312556Vanderbilt University Medical CenterTreatment of Supine Hypertension in Autonomic Failure (CPAP) | 2026-12-21 |
Add all 19 to your calendar (.ics) → With an account.
Among the 90 studies in Multiple System Atrophy with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main goal of this trial is to evaluate the efficacy and safety of amlenetug for the treatment of participants with Multiple System Atrophy (MSA).
This study will consist of a screening period of 10 days up to 6 weeks, a 72-week placebo-controlled period (PCP), and will include a 72-week optional open-label treatment extension (OLE) period. Participants in the PCP will be randomized to amlenetug or placebo. All participants entering the OLE will receive amlenetug during the OLE. Participants will receive intravenous infusions approximately every 4 weeks during both the PCP and OLE.
Key Inclusion Criteria:
Exclusion Criteria:
Other protocol-defined inclusion and exclusion criteria apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive amlenetug by intravenous infusion
Drug: Amlenetug
Participants will receive commercially available saline solution for infusion
Drug: Placebo
Solution for infusion
Also known as: Lu AF82422
Commercially available saline solution
Rest of the World (RoW; All Countries Except European Union [EU] and Japan [JP]) Regional-specific Outcome Measure: Mortality-adjusted Clinical Progression
Mortality-adjusted clinical progression will be assessed by the composite endpoint modified Unified Multiple System Atrophy Rating Scale (mUMSARS) score and time-to-death (any cause).
Time frame: Baseline up to Week 72
EU and JP Regional-specific Outcome Measure: Mortality-adjusted Clinical Progression
Mortality-adjusted clinical progression will be assessed by the composite endpoint Unified Multiple System Atrophy Rating Scale (UMSARS) Total Score (TS) and time-to-death (any cause).
Time frame: Baseline up to Week 72
RoW Regional-specific Outcome Measure: Mortality-adjusted Clinical Progression
Mortality-adjusted clinical progression will be assessed by the composite endpoint UMSARS TS and time-to-death (any cause).
Time frame: Baseline up to Week 72
EU and JP Regional-specific Outcome Measure: Change from Baseline in UMSARS TS
Time frame: Baseline, Week 72
RoW Regional-specific Outcome Measure: Change from Baseline in UMSARS TS
Time frame: Baseline, Week 72
Mortality-adjusted Clinical Progression
Mortality-adjusted clinical progression will be assessed by the composite endpoint UMSARS Part I and time-to-death (any cause).
Time frame: Baseline up to Week 72
Mortality-adjusted Clinical Progression
Mortality-adjusted clinical progression will be assessed by the composite endpoint UMSARS Part II and time-to-death (any cause).
Time frame: Baseline up to Week 72
Change from Baseline in mUMSARS Score
Time frame: Baseline, Week 72
Change from Baseline in UMSARS Part I Score
Time frame: Baseline, Week 72
Change from Baseline in UMSARS Part II Score
Time frame: Baseline, Week 72
Change from Baseline in Clinical Global Impression - Severity of Illness (CGI-S) Score
Time frame: Baseline, Week 72
Change from Baseline in Patient Global Impression - Severity of Illness (PGI-S) Score
Time frame: Baseline, Week 72
Change from Baseline in Observer-reported Global Impression-Severity of Illness (OGI-S) Score
Time frame: Baseline, Week 72
Change from Baseline in UMSARS Part IV Score
Time frame: Baseline, Week 72
Change from Baseline in Schwab and England Activities of Daily Living (SE-ADL) Score
Time frame: Baseline, Week 72
Change from Baseline in UMSARS Part I Item 1: Speech Score
Time frame: Baseline, Week 72
Time to Disability
Time frame: Baseline up to Week 72
Change from Baseline in EuroQol 5-dimensions, 5-levels (EQ-5D-5L) Domain Score
Time frame: Baseline, Week 72
Change from Baseline in EQ-5D-5L Visual Analog Scale (VAS) Score
Time frame: Baseline, Week 72
Change from Baseline in Multiple System Atrophy Quality of Life (MSA-QoL) Questionnaire Domain Scores
Time frame: Baseline, Week 72
Combined Clinical Progression and Survival Score
Time frame: Baseline, Week 72
Time from Baseline to Death (Any Cause)
Time frame: Baseline up to Week 72
Number of Participants with an Absolute Increase in mUMSARS Score of <5, <7, and <9 points
Time frame: Baseline to Week 72
Number of Participants with an Absolute Increase in UMSARS TS of <16, <21, and <26 Points
Time frame: Baseline to Week 72
Percentage Change from Baseline in Brain Volume in Brain Regions of Interest (ROIs)
Time frame: Baseline, Week 72
Area Under the Curve (AUC) of amlenetug
Time frame: Baseline up to Week 72
Maximum Observed Concentration (Cmax) of Amlenetug
Time frame: Baseline up to Week 72
Number of Participants with Treatment-emergent Adverse Events (TEAEs)
Time frame: Day 1 up to Week 144
Number of Participants with Anti-amlenetug Antibodies (ADAs)
Time frame: Baseline up to Week 144
Started Dec 2024 (actual). Primary completion is estimated for Feb 2028, 38 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Amlenetug